Form 4: Silence Therapeutics Director Richard Ian Griffiths Reports Significant Share Acquisitions

Director Richard Ian Griffiths reports acquiring Silence Therapeutics shares through Cream Capital Limited in multiple transactions.

Summary

• Richard Ian Griffiths, a director of Silence Therapeutics plc, reported changes in beneficial ownership.
• The transactions involved the purchase of American Depositary Shares (ADS) which are immediately convertible into three ordinary shares each.
• These purchases were made indirectly through Cream Capital Limited, where Mr. Griffiths is a director and controlling shareholder.
• On March 27, 2025, 50,000 ADS were purchased at $3.32 each.
• On March 28, 2025, another 50,000 ADS were purchased at $3.58 each.
• On March 31, 2025, 100,000 ADS were purchased at $3.46 each.
• Following these transactions, Mr. Griffiths indirectly beneficially owns 9,761,299 ordinary shares through Cream Capital Limited.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's purchase of shares could be interpreted as a sign of confidence, but the disclaimer of full beneficial ownership tempers the enthusiasm.

Positives

• Director's share purchases may signal confidence in the company's future prospects.

Management Comments

• Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

Industry Context

Directors' transactions are closely watched by investors as they can provide insights into the company's prospects. Increased ownership by insiders is generally viewed positively.

Stakeholder Impact

• Shareholders may view the director's share purchases as a positive signal.

Key Dates

Keywords

Silence Therapeutics, Richard Ian Griffiths, Cream Capital Limited, ADS, share acquisition, beneficial ownership, Form 4